The production of novel sordarin analogues by biotransformation.
The biotransformation of the fungal protein synthesis inhibitor sordarin is reported. Nine taxonomically diverse organisms supported the isolation and identification of twelve modified products. The structural diversity of the biotransformation products observed and their value in supporting further chemistry is discussed.
Hall
R M
RM
GlaxoSmithKline, Research and Development, Gene Expression and Protein Biochemistry, New Frontiers Science Park, Harlow, Essex, UK. Richard_m_Hall@gsk.com
Dawson
M J
MJ
Jones
C A
CA
Roberts
A D
AD
Sidebottom
P J
PJ
Stead
P
P
Taylor
N L
NL
D000935:Antifungal Agents / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D001711:Biotransformation; D002176:Candida albicans / Q000187:drug effects; D005285:Fermentation; D005658:Fungi / Q000737:chemistry / Q000378:metabolism*; D007192:Indenes; D008826:Microbial Sensitivity Tests; D011500:Protein Synthesis Inhibitors / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology
D000935:Antifungal Agents; D007192:Indenes; D011500:Protein Synthesis Inhibitors; C003329:sordarin